Atorvastatin associated liver disease.

  title={Atorvastatin associated liver disease.},
  author={Alexis Clarke and Peter R. Mills},
  journal={Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver},
  volume={38 10},
Atorvastatin, a HMG-CoA reductase inhibitor, is widely used in the treatment of dyslipidaemia. A transient rise in serum transaminases occurs in up to 3% of patients using atorvastatin but this is usually self-limiting and inconsequential. Recent literature has indicated some potential for more serious but rare idiosyncratic reactions related to this drug. Seven patients with significant liver dysfunction from one centre during 2002-2005 are reported, with one death, that raises some concern… CONTINUE READING


Publications citing this paper.
Showing 1-10 of 29 extracted citations

Statins alter the hepatobiliary transport of unconjugated and conjugated bilirubin in sandwich-cultured rat hepatocytes.

Toxicology in vitro : an international journal published in association with BIBRA • 2014
View 4 Excerpts
Highly Influenced

Hepatotoxicity of statins and other lipid-lowering agents.

Liver international : official journal of the International Association for the Study of the Liver • 2017
View 1 Excerpt

Similar Papers

Loading similar papers…